



CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test

Oslo, Norway and Kiel, Germany January 10, 2023: Cardiovascular DX company CardiNor AS today announces that it has signed an exclusive agreement with Demeditec for sales of the CE marked CardiNor Secretoneurin ELISA test in Germany. In addition, the agreement gives Demeditec the right to sell the test, on non-exclusive basis, in 15 countries outside Europe which includes India, South Korea, Mexico and Brazil.

The CardiNor Secretoneurin (SN) is a new biomarker test that could turn into a new gold-standard biomarker to monitor and treat millions of cardiac patients globally. SN has been shown to be a strong risk marker of mortality in several patient groups including ventricular arrhythmia, chronic heart failure and in patients with severe respiratory problems and sepsis. Thus, SN provides valuable prognostic information independent of established cardiovascular biomarkers.

Dr. Arndt Stüber, General Manager Demeditec, comments:

"The field of cardiovascular diseases is becoming an important part of our core business and thus CardiNor's Secretoneurin ELISA test is an excellent addition to our portfolio. We are convinced that our customers in the different territories will be offered an excellent diagnostic tool for research and routine".

Dag Christiansen, CEO CardiNor, comments:

"We are delighted to work with Demeditec Diagnostics, a company with extensive experience in distributing high quality laboratory research and clinical products in Germany and worldwide. Demeditec has a very strong position in the German market and the fact that they have an extensive network of partners in many countries around the world do provide CardiNor with an almost global market presence for our first-generation SN test".

More information can be found at: cardinor.com and demeditec.com

For further information, please contact:

CardiNor AS
Dag Christiansen, CEO
Email: dag.chr@cardinor.com
Phone: +47-92254855

Demeditec Diagnostics GmbH
Dr. Arndt Stüber, General Manager
Email: stueber@demeditec.de
Phone: +49 (0) 431 71922 60

About SN

Secretoneurin (SN) is associated with biological processes linked to heart cell calcium handling, a key mechanism in the regulation of heart rhythm^{1,2}, this in contrast to other commonly used biomarkers such as cardiac troponins and NT-proBNP. This unique biological function may explain why SN has been shown to be an independent and strong predictor of mortality in all major patient cohorts tested, including patients with chronic heart failure, ventricular arrhythmia, acute heart failure, and acute respiratory failure patients with CVD and severe sepsis^{2,3,4,5,6}. CardiNor has a comprehensive clinical program to further strengthen and widen the clinical documentation. The CardiNor SN assay is based on work by Professor Torbjørn Omland and his research group at Akershus University Hospital in Norway.

About CardiNor

CardiNor is a Norwegian Diagnostics company founded in 2015 with the purpose of fighting the Heart Failure (HF) epidemic, by leveraging the patented and exclusive rights to the commercial introduction of secretoneurin (SN), a blood-based biomarker that provides prognostic insights for several cardiovascular diseases (CVD). The team is focused on developing scalable cardiac biomarker tests to quantify the levels of SN in human blood, addressing a vast and untapped market potential in CVD patient diagnosis, risk stratification and monitoring.

About Demeditec Diagnostics GmbH

Demeditec Diagnostics GmbH is a privately owned company located in northern Germany. Since the foundation in 1987 Demeditec has rapidly grown to become a successful and reliable manufacturer and supplier of in-vitro diagnostic test kits. We are, therefore, proud to present an extensive product panel of non-radioactive (ELISA) and radioactive (RIA) test systems. The top-selling products of Demeditec are covering Human and Veterinary Diagnostics focusing on Endocrinology, Infectious Diseases, Autoimmunity, Biogenic Amines, Food Analytics, and other specialties. Moreover, recently the field of cardiovascular diseases is becoming an important part of our core business. To ensure the quality of our products, services, and support, Demeditec has been certified according to EN ISO 9001 and EN ISO 13485 since 2003. These certifications, along with qualified and creative expertise, enable us to develop innovative test kits for providing improved diagnostic outcomes.

Besides the domestic market, our customers are located worldwide on all continents including private laboratories, hospitals, universities as well as other research institutions and pharmaceutical companies.

References:

1. **Mark E. Anderson**, Editorial: Will Secretoneurin Be the Next Big Thing? J Am Coll Cardiol 2015,65
2. **Ottesen et.al**, Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol 2015 Feb 3;65(4):339-351
3. **Røsjø et.al**, on behalf of the FINNSEPSIS and FINNALI Study Groups. Prognostic Value of Secretoneurin in Critically Ill Patients with Infections. Crit. Care Med 2016 Oct;44(10):1882-90
4. **Myhre et.al**, Prognostic Value of Secretoneurin in Patients with Acute Respiratory Failure: Data from the FINNALI Study. Clin Chem 2016 Oct;62(10):1380-89
5. **Røsjø et al**, for the ALBIOS Biomarkers Study Investigators. Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock: Data From the Albumin Italian Outcome Sepsis Study. Crit Care Med 2018.
6. **Røsjø et al**, Circulating secretoneurin concentrations provide independent prognostic information to established risk indices in patients with chronic heart failure. Eur Heart J, Volume 43, Issue Supplement_2, October 2022